SCHEMBL6154313

SCHEMBL6154313

NC(=O)c1cc(F)c(NC2CCNCC2)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MELK Q14680 2/20 0.40
IRAK4 Q9NWZ3 1/20 0.37
BRD4 O60885 1/20 0.37
ATAD2 Q6PL18 1/20 0.37
ROCK2 O75116 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
P2RX7 Q99572 1/20 0.36
PRKD1 Q15139 4/20 0.36
PRKD2 Q9BZL6 4/20 0.36
HTR4 Q13639 1/20 0.36
AURKA O14965 1/20 0.36
RPS6KB1 P23443 1/20 0.36
BTK Q06187 2/20 0.35
CHEK1 O14757 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
ADRB1 P08588 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154506 0.76 ROCK2 (0.47) IRAK4BRD4ATAD2ROCK2CDK5
SCHEMBL6154711 0.76 TOP2A (0.47) IRAK4BRD4ATAD2P2RX7AURKA
SCHEMBL6154956 0.74 ROCK2 (0.58) MELKROCK2P2RX7HTR4AURKA
SCHEMBL6154636 0.72 TOP2A (0.46) PRKD1PRKD2CHEK1
SCHEMBL6153331 0.71 ROCK2 (0.40) ROCK2CDK5CDK5R1AURKARPS6KB1
SCHEMBL27644625 0.70 KDM1A (0.40) CDK5CDK5R1
SCHEMBL6154865 0.70 ROCK2 (0.72) ROCK2CDK5CDK5R1AURKARPS6KB1
SCHEMBL6156929 0.68 MAPK14 (0.47) PRKD1PRKD2RPS6KB1CHEK1
SCHEMBL4144350 0.68 IRAK4 (0.45) IRAK4BRD4ATAD2P2RX7AURKA
SCHEMBL17699912 0.68 BTK (0.71) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 MELK 2442/4885IRAK4 3240/4885BRD4 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.